In the frame of the  scientific meetings Biotechnology Havana,  the 2010 edition will be devoted to the “INTEGRAL CARE OF DIABETIC FOOT ULCER PATIENT USING HEBERPROT-P”, which will be held at  the Center for Genetic Engineering and Biotechnology (CIGB) of Havana, Cuba.

Today Diabetes affects more than 300 million people worldwide, where diabetic foot ulcers (DFU) are among its main complications with worse medical evolution and higher resources drained from health systems. Since its registration in Cuba in 2006, the Heberprot-P efficacy and safety has been demonstrated combining “evidence based study facts” regarding successful clinical trials phase I, II and III execution and “experience based study facts” regarding clinical experience accumulated in more than 13500 treated patients from Cuba, Venezuela, Algeria and Argentina. Today Heberprot-P is a main part of the basic frame of drugs aimed at the diabetic foot ulcer (DFU) therapy in Cuba.

The therapy with Heberprot-P® fills the gap of an urgent unmet medical need for the treatment of complex DFU. Heberprot-P is a novel and unique medicine indicated for DFU treatment. Its innovative achievement is based on the action of the  recombinant human epidermal growth factor (rhEGF) used as active pharmaceutical ingredient (API) and applied by intralesional infiltration directly into the wound site.

Previous editions of Biotechnology Havana have gathered about 800 participants from more than 30 countries. Renowned specialists have delivered Plenary Conferences and Key Lectures including Nobel Laureates in Medicine and Chemistry, among them, Prof. Stanley Cohen, the scientist who discovered and characterized the epidermal growth factor, a key molecule in Heberprot-P® formulation, who attended the BH2003 edition. The Havana Biotechnology congress counts with large National and International participation due to their high scientific level, the Poster sessions and the open and frankly atmosphere created for discussions and experience exchanges.

The BH2010 Congress will be held from 20 to 22nd October 2010 but now incorporating a change based in integrating Symposia two and three into a single one in order to facilitate the exchange of experiences between different DFU specialists, so now BH2010 will hold two main Symposia: The first symposium maintain its focus in the Molecular biology of the epidermal growth factor (EGF) and the pharmacogenomic of drugs based in EGF, and the second symposium will cover the current status of the integral care of Diabetic Foot Ulcer patients worldwide.

It is our intention also to take advantage of the BH2010 Congress Organization to launch a call for considering as an option to participate in a Pre-Congress Course-Workshop: Practical application of Heberprot-P in diabetic foot ulcers, with the purpose to share mainly to international specialists practical procedures for applying Heberprot-P in DFU. The Course-Workshop will be held during 18-19th October, at the facilities of the prestigious Research Center for Medical Surgery (CIMEQ) in Havana, Cuba.

Hoping to count with your participation in BH2010 next October, Sincerely

Dr. Luis Herrera

President of the BH 2010 Organizing Committee and CIGB General Director